NEDD 8 pathway inhibition is effective in preclinical models of poorly differentiated , clinically aggressive colorectal cancer
暂无分享,去创建一个
F. Nicolantonio | A. Bardelli | A. Sapino | C. Isella | C. Petti | A. Bertotti | E. Medico | G. Migliardi | F. Sassi | Lívio | G. Picco | Teresa Rossi | K. Grillone | Trusolino | Giorgia Migliardi | Consalvo Petti
[1] K. Okuno,et al. Clinicopathological and genetic differences between low‐grade and high‐grade colorectal mucinous adenocarcinomas , 2015, Cancer.
[2] M. Linnebacher,et al. Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype , 2015, PloS one.
[3] Hong-Chiang Chang,et al. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma , 2015, Scientific Reports.
[4] G. Mulligan,et al. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma , 2015, Clinical Cancer Research.
[5] F. Wolenski,et al. The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis , 2015, Cell Death Discovery.
[6] R. Scharpf,et al. The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.
[7] Jeffrey W. Clark,et al. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.
[8] P. Chen,et al. The novel protective role of P27 in MLN4924-treated gastric cancer cells , 2015, Cell Death and Disease.
[9] J. Brown,et al. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents , 2015, Cell Death and Disease.
[10] M. Maris,et al. Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study , 2015, British journal of haematology.
[11] Marco Beccuti,et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets , 2015, Nature Communications.
[12] G. Inghirami,et al. Stromal contribution to the colorectal cancer transcriptome , 2015, Nature Genetics.
[13] M. Linnebacher,et al. Establishment and characterization of cell lines from chromosomal instable colorectal cancer. , 2015, World journal of gastroenterology.
[14] J. Maciejewski,et al. The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine , 2014, Clinical Cancer Research.
[15] A. Bardelli,et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.
[16] N. I. Pospekhova,et al. Epithelial-Mesenchymal Transition and Somatic Alteration in Colorectal Cancer with and without Peritoneal Carcinomatosis , 2014, BioMed research international.
[17] T. Rikiyama,et al. Molecular biomarkers for the detection of metastatic colorectal cancer cells. , 2014, World journal of gastroenterology.
[18] E. Lightcap,et al. Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways , 2014, Molecular Cancer Therapeutics.
[19] D. Zecchin,et al. BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors , 2013, Molecular Cancer Therapeutics.
[20] A. Jazaeri,et al. Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924 , 2013, Molecular Cancer Therapeutics.
[21] Seung-Yong Jeong,et al. Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy , 2013, British Journal of Cancer.
[22] Peter G. Smith,et al. Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Ostwald,et al. Establishment, Characterization and Chemosensitivity of Three Mismatch Repair Deficient Cell Lines from Sporadic and Inherited Colorectal Carcinomas , 2012, PloS one.
[24] R. Yantiss,et al. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. , 2012, American journal of clinical pathology.
[25] C. Kunisaki,et al. The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease , 2012, World Journal of Surgical Oncology.
[26] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[27] Yi Sun,et al. The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme , 2012, PloS one.
[28] I. Nagtegaal,et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. , 2012, European journal of cancer.
[29] Hirohito Yamaguchi,et al. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. , 2012, Cancer research.
[30] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[31] F. Khuri,et al. The NEDD8-Activating Enzyme Inhibitor, MLN4924, Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells , 2011, Molecular Cancer Therapeutics.
[32] Lijun Jia,et al. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. , 2011, Neoplasia.
[33] F. Cebrià,et al. EGFR signaling regulates cell proliferation, differentiation and morphogenesis during planarian regeneration and homeostasis. , 2011, Developmental biology.
[34] Thomas Hartmann,et al. The cullin protein family , 2011, Genome Biology.
[35] M. Ohh,et al. NEDD8 pathways in cancer, Sine Quibus Non. , 2011, Cancer cell.
[36] David B Jackson,et al. EMT is the dominant program in human colon cancer , 2011, BMC Medical Genomics.
[37] Anindya Dutta,et al. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. , 2010, Cancer research.
[38] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[39] T. Ørntoft,et al. Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer , 2009, Clinical Cancer Research.
[40] Peter G. Smith,et al. Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer , 2009, Clinical Cancer Research.
[41] Amanda Doucette,et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.
[42] D. Hedley,et al. Cancer stem cells, hypoxia and metastasis. , 2009, Seminars in radiation oncology.
[43] F. Caponigro,et al. The ubiquitin–proteasome system as a molecular target in solid tumors: an update on bortezomib , 2009, OncoTargets and therapy.
[44] M. Peter,et al. Function and regulation of protein neddylation , 2008, EMBO reports.
[45] Kou-Juey Wu,et al. Direct regulation of TWIST by HIF-1α promotes metastasis , 2008, Nature Cell Biology.
[46] Manuel Hidalgo,et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[48] L. Schwartz,et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Michael Peyton,et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.
[50] E. Yeh,et al. Characterization of NEDD8, a Developmentally Down-regulated Ubiquitin-like Protein* , 1997, The Journal of Biological Chemistry.
[51] Hua Li,et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. , 2012, Cancer research.
[52] D. Lacombe,et al. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. , 2009, European journal of cancer.
[53] Z. Hua. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .